Victory Capital Management Inc. Has $5.05 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Victory Capital Management Inc. raised its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 112.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 146,609 shares of the company's stock after purchasing an additional 77,611 shares during the period. Victory Capital Management Inc. owned approximately 0.26% of Harmony Biosciences worth $5,045,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. lifted its holdings in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Harmony Biosciences by 27.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock worth $26,416,000 after acquiring an additional 140,690 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Harmony Biosciences by 27.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company's stock worth $16,242,000 after acquiring an additional 100,586 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Harmony Biosciences by 13.8% during the 4th quarter. Bank of New York Mellon Corp now owns 265,639 shares of the company's stock worth $9,141,000 after acquiring an additional 32,272 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after acquiring an additional 93,622 shares during the period. Institutional investors own 86.23% of the company's stock.

Remove Ads

Harmony Biosciences Trading Up 4.2 %

NASDAQ HRMY traded up $1.37 on Monday, hitting $34.09. The company's stock had a trading volume of 144,718 shares, compared to its average volume of 621,585. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company's 50-day moving average is $36.40 and its 200 day moving average is $35.63. The firm has a market cap of $1.95 billion, a PE ratio of 16.10, a PEG ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. During the same period in the prior year, the company posted $0.45 EPS. The company's revenue was up 19.5% on a year-over-year basis. As a group, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

HRMY has been the subject of a number of recent analyst reports. Mizuho cut their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating for the company in a report on Thursday, February 20th. HC Wainwright dropped their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $53.11.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 over the last three months. 30.80% of the stock is owned by company insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.